Review



trade name drug target s molecule type developer s owner fda approval  (Novartis)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Novartis trade name drug target s molecule type developer s owner fda approval
    Trade Name Drug Target S Molecule Type Developer S Owner Fda Approval, supplied by Novartis, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/trade+name+drug+target+s+molecule+type+developer+s+owner+fda+approval/accelerated+approval+fabhalta+fda+for+iptacopan/pm41052545-198-0-15
    Average 86 stars, based on 1 article reviews
    trade name drug target s molecule type developer s owner fda approval - by Bioz Stars, 2026-09
    86/100 stars

    Images

    Related Articles

    other:

    Article Title: From Large to Small Cytokine Receptor Antagonists.
    Article Snippet: Trade Name Drug Target(s) Molecule Type Developer(s) Owner FDA Approval Year Cosentyx Secukinumab IL-17A mAB Novartis Novartis 2015 Taltz Ixekizumab IL-17A mAB Eli Lilly Eli Lilly 2016 Siliq Brodalumab IL-17RA mAB Valeant AstraZeneca Bausch Health 2017 Bimzelx Bimekizumab IL-17A IL-17F mAB UCB UCB 2023 Table 4: Key Anti-IL-17 Biological Drugs Key disease indications for anti-IL-17 drugs include autoimmune diseases, such as psoriasis, ankylosing spondylitis, and hidradenitis suppurativa.



    Similar Products

    trade name drug target s molecule type developer s owner fda approval  (Novartis)
    86
    Novartis trade name drug target s molecule type developer s owner fda approval
    Trade Name Drug Target S Molecule Type Developer S Owner Fda Approval, supplied by Novartis, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/trade+name+drug+target+s+molecule+type+developer+s+owner+fda+approval/accelerated+approval+fabhalta+fda+for+iptacopan/pm41052545-198-0-15
    Average 86 stars, based on 1 article reviews
    trade name drug target s molecule type developer s owner fda approval - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier

    Image Search Results